Prosecution Insights
Prosecution Insights
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWE, DAVID | 1 | 25.8% | +28.7% |
| CABRAL, ROBERT S | 1 | 62.3% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270361 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | BROWE, DAVID | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | CABRAL, ROBERT S | 12d |
| 18270361 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | BROWE, DAVID | 26d |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270361 | TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY | BROWE, DAVID | 1617 | §103 | Non-Final OA | 26d | Pending | Jun 29, 2023 |
| 18215550 | NANOPARTICLES AND TEMPLATE DIRECTED RIG-I AGONIST PRECURSOR COMPOSITIONS AND USES THEREOF FOR CANCER THERAPY | CABRAL, ROBERT S | 1614 | Other | Non-Final OA | 12d | Pending | Jun 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial